Reactivation of embryonic genetic programs in tissue regeneration and disease.
Journal
Nature genetics
ISSN: 1546-1718
Titre abrégé: Nat Genet
Pays: United States
ID NLM: 9216904
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
10
01
2023
accepted:
11
09
2023
medline:
10
11
2023
pubmed:
31
10
2023
entrez:
31
10
2023
Statut:
ppublish
Résumé
Embryonic genetic programs are reactivated in response to various types of tissue damage, providing cell plasticity for tissue regeneration or disease progression. In acute conditions, these programs remedy the damage and then halt to allow a return to homeostasis. In chronic situations, including inflammatory diseases, fibrosis and cancer, prolonged activation of embryonic programs leads to disease progression and tissue deterioration. Induction of progenitor identity and cell plasticity, for example, epithelial-mesenchymal plasticity, are critical outcomes of reactivated embryonic programs. In this Review, we describe molecular players governing reactivated embryonic genetic programs, their role during disease progression, their similarities and differences and lineage reversion in pathology and discuss associated therapeutics and drug-resistance mechanisms across many organs. We also discuss the diversity of reactivated programs in different disease contexts. A comprehensive overview of commonalities between development and disease will provide better understanding of the biology and therapeutic strategies.
Identifiants
pubmed: 37904052
doi: 10.1038/s41588-023-01526-4
pii: 10.1038/s41588-023-01526-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1792-1806Informations de copyright
© 2023. Springer Nature America, Inc.
Références
Virchow, R. L. K. Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre (A. Hirschwald, 1859).
Fazilaty, H. Restoration of embryonic gene expression patterns in tissue regeneration and disease. Nat. Rev. Mol. Cell Biol. 24, 375–376 (2023).
Peluffo, A. E. The ‘genetic program’: behind the genesis of an influential metaphor. Genetics 200, 685–696 (2015).
pubmed: 26170444
pmcid: 4512536
doi: 10.1534/genetics.115.178418
Malta, T. M. et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell 173, 338–354 (2018).
pubmed: 29625051
pmcid: 5902191
doi: 10.1016/j.cell.2018.03.034
Hnisz, D. et al. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol. Cell 58, 362–370 (2015).
pubmed: 25801169
pmcid: 4402134
doi: 10.1016/j.molcel.2015.02.014
Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307–319 (2013).
pubmed: 23582322
pmcid: 3653129
doi: 10.1016/j.cell.2013.03.035
Bala, P. et al. Aberrant cell state plasticity mediated by developmental reprogramming precedes colorectal cancer initiation. Sci. Adv. 9, eadf0927 (2023).
pubmed: 36989360
pmcid: 10058311
doi: 10.1126/sciadv.adf0927
Fazilaty, H. et al. Tracing colonic embryonic transcriptional profiles and their reactivation upon intestinal damage. Cell Rep. 36, 109484 (2021).
pubmed: 34348153
doi: 10.1016/j.celrep.2021.109484
Varum, S. et al. Yin yang 1 orchestrates a metabolic program required for both neural crest development and melanoma formation. Cell Stem Cell 24, 637–653 (2019).
Rehman, S. K. et al. Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell 184, 226–242 (2021).
pubmed: 33417860
doi: 10.1016/j.cell.2020.11.018
Dhimolea, E. et al. An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence. Cancer Cell 39, 240–256 (2021).
pubmed: 33417832
pmcid: 8670073
doi: 10.1016/j.ccell.2020.12.002
Jatiani, S. S. et al. SOX11 inhibitors are cytotoxic in mantle cell lymphoma. Clin. Cancer Res. 27, 4652–4663 (2021).
pubmed: 34158358
pmcid: 8364871
doi: 10.1158/1078-0432.CCR-20-5039
Grande, M. T. et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat. Med. 21, 989–997 (2015).
pubmed: 26236989
doi: 10.1038/nm.3901
Burdziak, C. et al. Epigenetic plasticity cooperates with cell–cell interactions to direct pancreatic tumorigenesis. Science 380, eadd5327 (2023).
Moorman, A. R. et al. Progressive plasticity during colorectal cancer metastasis. Preprint at bioRxiv https://doi.org/10.1101/2023.08.18.553925 (2023).
Li, Y. et al. Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer. Nat. Cancer 2, 49–65 (2021).
pubmed: 35121887
doi: 10.1038/s43018-020-00134-z
Hill, W. et al. Lung adenocarcinoma promotion by air pollutants. Nature 616, 159–167 (2023).
pubmed: 37020004
pmcid: 7614604
doi: 10.1038/s41586-023-05874-3
Salgia, R. & Kulkarni, P. The genetic/non-genetic duality of drug ‘resistance’ in cancer. Trends Cancer 4, 110–118 (2018).
pubmed: 29458961
pmcid: 5822736
doi: 10.1016/j.trecan.2018.01.001
Shivdasani, R. A., Clevers, H. & de Sauvage, F. J. Tissue regeneration: reserve or reverse? Science 371, 784–786 (2021).
pubmed: 33602845
doi: 10.1126/science.abb6848
Sun, Q. et al. Dedifferentiation maintains melanocyte stem cells in a dynamic niche. Nature 616, 774–782 (2023).
pubmed: 37076619
pmcid: 10132989
doi: 10.1038/s41586-023-05960-6
Bhartiya, D. Adult tissue-resident stem cells—fact or fiction? Stem Cell Res. Ther. 12, 73 (2021).
Yui, S. et al. YAP/TAZ-dependent reprogramming of colonic epithelium links ECM remodeling to tissue regeneration. Cell Stem Cell 22, 35–49 (2018).
Del Poggetto, E. et al. Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science 373, eabj0486 (2021).
pubmed: 34529467
pmcid: 9733946
doi: 10.1126/science.abj0486
Nusse, Y. M. et al. Parasitic helminths induce fetal-like reversion in the intestinal stem cell niche. Nature 559, 109–113 (2018).
pubmed: 29950724
pmcid: 6042247
doi: 10.1038/s41586-018-0257-1
Mustata, R. C. et al. Identification of Lgr5-independent spheroid-generating progenitors of the mouse fetal intestinal epithelium. Cell Rep. 5, 421–432 (2013).
pubmed: 24139799
doi: 10.1016/j.celrep.2013.09.005
Househam, J. et al. Phenotypic plasticity and genetic control in colorectal cancer evolution. Nature 611, 744–753 (2022).
Laughney, A. M. et al. Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nat. Med. 26, 259–269 (2020).
pubmed: 32042191
pmcid: 7021003
doi: 10.1038/s41591-019-0750-6
Perino, M. & Veenstra, G. J. C. Chromatin control of developmental dynamics and plasticity. Dev. Cell 38, 610–620 (2016).
pubmed: 27676434
doi: 10.1016/j.devcel.2016.08.004
Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).
pubmed: 35022204
doi: 10.1158/2159-8290.CD-21-1059
Hayashi, A., Hong, J. & Iacobuzio-Donahue, C. A. The pancreatic cancer genome revisited. Nat. Rev. Gastroenterol. Hepatol. 18, 469–481 (2021).
pubmed: 34089011
doi: 10.1038/s41575-021-00463-z
Dagogo-Jack, I. et al. Clinicopathologic characteristics of BRG1-deficient NSCLC. J. Thorac. Oncol. 15, 766–776 (2020).
pubmed: 31988001
doi: 10.1016/j.jtho.2020.01.002
Kleppe, A. et al. Chromatin organisation and cancer prognosis: a pan-cancer study. Lancet Oncol. 19, 356–369 (2018).
pubmed: 29402700
pmcid: 5842159
doi: 10.1016/S1470-2045(17)30899-9
Kim, Y. J. et al. Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapy. J. Clin. Invest. 131, e145859 (2021).
pubmed: 33914706
pmcid: 8203459
doi: 10.1172/JCI145859
Yang, J. et al. Guidelines and definitions for research on epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol. 21, 341–352 (2020).
pubmed: 32300252
pmcid: 7250738
doi: 10.1038/s41580-020-0237-9
Thiery, J. P., Acloque, H., Huang, R. Y. J. & Nieto, M. A. Epithelial–mesenchymal transitions in development and disease. Cell 139, 871–890 (2009).
pubmed: 19945376
doi: 10.1016/j.cell.2009.11.007
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A. & Thiery, J. P. EMT: 2016. Cell 166, 21–45 (2016).
pubmed: 27368099
doi: 10.1016/j.cell.2016.06.028
Brabletz, T., Kalluri, R., Nieto, M. A. & Weinberg, R. A. EMT in cancer. Nat. Rev. Cancer 18, 128–134 (2018).
pubmed: 29326430
doi: 10.1038/nrc.2017.118
Fazilaty, H. et al. A gene regulatory network to control EMT programs in development and disease. Nat. Commun. 10, 5115 (2019).
pubmed: 31712603
pmcid: 6848104
doi: 10.1038/s41467-019-13091-8
Zhang, Y. et al. Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis. Nat. Cell Biol. 24, 554–564 (2022).
pubmed: 35411083
pmcid: 9037576
doi: 10.1038/s41556-022-00877-0
Lambert, A. W. & Weinberg, R. A. Linking EMT programmes to normal and neoplastic epithelial stem cells. Nat. Rev. Cancer 21, 325–338 (2021).
pubmed: 33547455
doi: 10.1038/s41568-021-00332-6
Shaw, T. J. & Martin, P. Wound repair: a showcase for cell plasticity and migration. Curr. Opin. Cell Biol. 42, 29–37 (2016).
pubmed: 27085790
doi: 10.1016/j.ceb.2016.04.001
Frangogiannis, N. G. Transforming growth factor-β in tissue fibrosis. J. Exp. Med. 217, e20190103 (2020).
pubmed: 32997468
pmcid: 7062524
doi: 10.1084/jem.20190103
Scharl, M. et al. Hallmarks of epithelial to mesenchymal transition are detectable in Crohn’s disease associated intestinal fibrosis. Clin. Transl. Med. 4, 1 (2015).
pubmed: 25852817
pmcid: 4384762
doi: 10.1186/s40169-015-0046-5
Scharl, M. & Rogler, G. Pathophysiology of fistula formation in Crohn’s disease. World J. Gastrointest. Pathophysiol. 5, 205–212 (2014).
pubmed: 25133023
pmcid: 4133520
doi: 10.4291/wjgp.v5.i3.205
Rout-Pitt, N., Farrow, N., Parsons, D. & Donnelley, M. Epithelial mesenchymal transition (EMT): a universal process in lung diseases with implications for cystic fibrosis pathophysiology. Respir. Res. 19, 136 (2018).
Su, J. et al. TGF-β orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1. Nature 577, 566–571 (2020).
pubmed: 31915377
pmcid: 7450666
doi: 10.1038/s41586-019-1897-5
Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580–584 (2013).
pubmed: 23372014
pmcid: 3760262
doi: 10.1126/science.1228522
Lüönd, F. et al. Distinct contributions of partial and full EMT to breast cancer malignancy. Dev. Cell 56, 3203–3221 (2021).
pubmed: 34847378
doi: 10.1016/j.devcel.2021.11.006
Nieto, M. A. Context-specific roles of EMT programmes in cancer cell dissemination. Nat. Cell Biol. 19, 416–418 (2017).
pubmed: 28446813
doi: 10.1038/ncb3520
Pastushenko, I. et al. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature 589, 448–455 (2021).
pubmed: 33328637
doi: 10.1038/s41586-020-03046-1
Lehmann, W. et al. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat. Commun. 7, 10498 (2016).
pubmed: 26876920
pmcid: 4756710
doi: 10.1038/ncomms10498
Sreekumar, R. et al. Assessment of nuclear ZEB2 as a biomarker for colorectal cancer outcome and TNM risk stratification. JAMA Netw. Open 1, e183115 (2018).
pubmed: 30646224
pmcid: 6324431
doi: 10.1001/jamanetworkopen.2018.3115
Marie, K. L. et al. Melanoblast transcriptome analysis reveals pathways promoting melanoma metastasis. Nat. Commun. 11, 333 (2020).
pubmed: 31949145
pmcid: 6965108
doi: 10.1038/s41467-019-14085-2
Soldatov, R. et al. Spatiotemporal structure of cell fate decisions in murine neural crest. Science 364, eaas9536 (2019).
pubmed: 31171666
doi: 10.1126/science.aas9536
Karras, P. et al. A cellular hierarchy in melanoma uncouples growth and metastasis. Nature 610, 190–198 (2022).
pubmed: 36131018
pmcid: 10439739
doi: 10.1038/s41586-022-05242-7
Semaan, A. et al. Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer. Br. J. Cancer 124, 1970–1977 (2021).
pubmed: 33785875
pmcid: 8185080
doi: 10.1038/s41416-021-01350-9
Aceto, N. et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158, 1110–1122 (2014).
pubmed: 25171411
pmcid: 4149753
doi: 10.1016/j.cell.2014.07.013
Donato, C. et al. Hypoxia triggers the intravasation of clustered circulating tumor cells. Cell Rep. 32, 108105 (2020).
pubmed: 32905777
pmcid: 7487783
doi: 10.1016/j.celrep.2020.108105
Bonnomet, A. et al. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 31, 3741–3753 (2012).
pubmed: 22120722
doi: 10.1038/onc.2011.540
Ting, D. T. et al. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 8, 1905–1918 (2014).
pubmed: 25242334
pmcid: 4230325
doi: 10.1016/j.celrep.2014.08.029
Ruscetti, M., Quach, B., Dadashian, E. L., Mulholland, D. J. & Wu, H. Tracking and functional characterization of epithelial–mesenchymal transition and mesenchymal tumor cells during prostate cancer metastasis. Cancer Res. 75, 2749–2759 (2015).
pubmed: 25948589
pmcid: 4490048
doi: 10.1158/0008-5472.CAN-14-3476
Mani, S. A. et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008).
pubmed: 18485877
pmcid: 2728032
doi: 10.1016/j.cell.2008.03.027
Fazilaty, H., Gardaneh, M., Akbari, P., Zekri, A. & Behnam, B. SLUG and SOX9 cooperatively regulate tumor initiating niche factors in breast cancer. Cancer Microenviron. 9, 71–74 (2016).
pubmed: 26412079
doi: 10.1007/s12307-015-0176-8
Celià-Terrassa, T. et al. Epithelial–mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J. Clin. Invest. 122, 1849–1868 (2012).
pubmed: 22505459
pmcid: 3366719
doi: 10.1172/JCI59218
Ocaña, O. H. et al. Metastatic colonization requires the repression of the epithelial–mesenchymal transition inducer Prrx1. Cancer Cell 22, 709–724 (2012).
pubmed: 23201163
doi: 10.1016/j.ccr.2012.10.012
Pastushenko, I. et al. Identification of the tumour transition states occurring during EMT. Nature 556, 463–468 (2018).
pubmed: 29670281
doi: 10.1038/s41586-018-0040-3
Bartel, D. P. Metazoan microRNAs. Cell 173, 20–51 (2018).
pubmed: 29570994
pmcid: 6091663
doi: 10.1016/j.cell.2018.03.006
Cano, A. & Nieto, M. A. Non-coding RNAs take centre stage in epithelial-to-mesenchymal transition. Trends Cell Biol. 18, 357–359 (2008).
pubmed: 18585040
doi: 10.1016/j.tcb.2008.05.005
Rago, L. et al. MicroRNAs establish the right-handed dominance of the heart laterality pathway in vertebrates. Dev. Cell 51, 446–459 (2019).
pubmed: 31630980
doi: 10.1016/j.devcel.2019.09.012
Díaz-López, A., Moreno-Bueno, G. & Cano, A. Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Manag. Res. 6, 205–216 (2014).
pubmed: 24812525
pmcid: 4008290
Monzo, M. et al. Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res. 18, 823–833 (2008).
pubmed: 18607389
doi: 10.1038/cr.2008.81
Saghafinia, S. et al. Cancer cells retrace a stepwise differentiation program during malignant progression. Cancer Discov. 11, 2638–2657 (2021).
pubmed: 33910926
pmcid: 7611766
doi: 10.1158/2159-8290.CD-20-1637
Lee, J. H. & Massagué, J. TGF-β in developmental and fibrogenic EMTs. Semin. Cancer Biol. 86, 136–145 (2022).
pubmed: 36183999
pmcid: 10155902
doi: 10.1016/j.semcancer.2022.09.004
Rim, E. Y., Clevers, H. & Nusse, R. The Wnt pathway: from signaling mechanisms to synthetic modulators. Annu. Rev. Biochem. 91, 571–598 (2022).
pubmed: 35303793
doi: 10.1146/annurev-biochem-040320-103615
Gregorieff, A., Liu, Y., Inanlou, M. R., Khomchuk, Y. & Wrana, J. L. Yap-dependent reprogramming of Lgr5
pubmed: 26503053
doi: 10.1038/nature15382
Solé, L. et al. p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis. Nat. Commun. 13, 2866 (2022).
pubmed: 35606354
pmcid: 9126967
doi: 10.1038/s41467-022-30382-9
Jacquemin, G. et al. Paracrine signalling between intestinal epithelial and tumour cells induces a regenerative programme. eLife 11, e76541 (2022).
pubmed: 35543624
pmcid: 9094746
doi: 10.7554/eLife.76541
Er, E. E. et al. Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. Nat. Cell Biol. 20, 966–978 (2018).
pubmed: 30038252
pmcid: 6467203
doi: 10.1038/s41556-018-0138-8
Ganesh, K. et al. L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer. Nat. Cancer 1, 28–45 (2020).
pubmed: 32656539
pmcid: 7351134
doi: 10.1038/s43018-019-0006-x
Altevogt, P. et al. Recent insights into the role of L1CAM in cancer initiation and progression. Int. J. Cancer 147, 3292–3296 (2020).
pubmed: 32588424
doi: 10.1002/ijc.33177
Zhang, W. et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci. Signal. 7, ra42 (2014).
pubmed: 24803537
pmcid: 4175524
doi: 10.1126/scisignal.2005049
Wu, B.-K., Mei, S.-C., Chen, E. H., Zheng, Y. & Pan, D. YAP induces an oncogenic transcriptional program through TET1-mediated epigenetic remodeling in liver growth and tumorigenesis. Nat. Genet. 54, 1202–1213 (2022).
pubmed: 35835915
pmcid: 9357225
doi: 10.1038/s41588-022-01119-7
Kowalczyk, W. et al. Hippo signaling instructs ectopic but not normal organ growth. Science 378, eabg3679 (2022).
Tiana, M. et al. Pluripotency factors regulate the onset of Hox cluster activation in the early embryo. Sci. Adv. 8, eabo3583 (2022).
pubmed: 35857513
pmcid: 9286507
doi: 10.1126/sciadv.abo3583
Li, M. & Belmonte, J. C. I. Ground rules of the pluripotency gene regulatory network. Nat. Rev. Genet. 18, 180–191 (2017).
pubmed: 28045100
doi: 10.1038/nrg.2016.156
Blassberg, R. et al. Sox2 levels regulate the chromatin occupancy of WNT mediators in epiblast progenitors responsible for vertebrate body formation. Nat. Cell Biol. 24, 633–644 (2022).
pubmed: 35550614
pmcid: 9106585
doi: 10.1038/s41556-022-00910-2
Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499–507 (2008).
pubmed: 18443585
pmcid: 2912221
doi: 10.1038/ng.127
Yong, K. J. et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N. Engl. J. Med. 368, 2266–2276 (2013).
pubmed: 23758232
pmcid: 3781214
doi: 10.1056/NEJMoa1300297
Hepburn, A. C. et al. The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance. Oncogene 38, 4412–4424 (2019).
pubmed: 30742096
pmcid: 6546609
doi: 10.1038/s41388-019-0712-y
Gkountela, S. et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell 176, 98–112 (2019).
pubmed: 30633912
pmcid: 6363966
doi: 10.1016/j.cell.2018.11.046
Lee, T. K. W. et al. CD24
Kim, J. et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 143, 313–324 (2010).
pubmed: 20946988
pmcid: 3018841
doi: 10.1016/j.cell.2010.09.010
Dhanasekaran, R. et al. The MYC oncogene — the grand orchestrator of cancer growth and immune evasion. Nat. Rev. Clin. Oncol. 19, 23–36 (2022).
pubmed: 34508258
doi: 10.1038/s41571-021-00549-2
Sodir, N. M. et al. MYC instructs and maintains pancreatic adenocarcinoma phenotype. Cancer Discov. 10, 588–607 (2020).
pubmed: 31941709
doi: 10.1158/2159-8290.CD-19-0435
Kortlever, R. M. et al. Myc cooperates with Ras by programming inflammation and immune suppression. Cell 171, 1301–1315 (2017).
pubmed: 29195074
pmcid: 5720393
doi: 10.1016/j.cell.2017.11.013
Sodir, N. M. et al. Reversible Myc hypomorphism identifies a key Myc-dependency in early cancer evolution. Nat. Commun. 13, 6782 (2022).
pubmed: 36351945
pmcid: 9646778
doi: 10.1038/s41467-022-34079-x
Lee-Six, H. et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature 574, 532–537 (2019).
pubmed: 31645730
doi: 10.1038/s41586-019-1672-7
Jo, A. et al. The versatile functions of Sox9 in development, stem cells, and human diseases. Genes Dis. 1, 149–161 (2014).
pubmed: 25685828
pmcid: 4326072
doi: 10.1016/j.gendis.2014.09.004
Campana, L., Esser, H., Huch, M. & Forbes, S. Liver regeneration and inflammation: from fundamental science to clinical applications. Nat. Rev. Mol. Cell Biol. 22, 608–624 (2021).
pubmed: 34079104
doi: 10.1038/s41580-021-00373-7
Ge, Y. et al. Stem cell lineage infidelity drives wound repair and cancer. Cell 169, 636–650 (2017).
pubmed: 28434617
pmcid: 5510746
doi: 10.1016/j.cell.2017.03.042
Drubbel, A. V. et al. Reactivation of the Hedgehog pathway in esophageal progenitors turns on an embryonic-like program to initiate columnar metaplasia. Cell Stem Cell 28, 1411–1427 (2021).
Guo, W. et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148, 1015–1028 (2012).
pubmed: 22385965
pmcid: 3305806
doi: 10.1016/j.cell.2012.02.008
Fazilaty, H., Gardaneh, M., Bahrami, T., Salmaninejad, A. & Behnam, B. Crosstalk between breast cancer stem cells and metastatic niche: emerging molecular metastasis pathway? Tumour Biol. 34, 2019–2030 (2013).
pubmed: 23686802
doi: 10.1007/s13277-013-0831-y
Hanieh, H., Ahmed, E. A., Vishnubalaji, R. & Alajez, N. M. SOX4: epigenetic regulation and role in tumorigenesis. Semin. Cancer Biol. 67, 91–104 (2020).
pubmed: 31271889
doi: 10.1016/j.semcancer.2019.06.022
Dravis, C. et al. Epigenetic and transcriptomic profiling of mammary gland development and tumor models disclose regulators of cell state plasticity. Cancer Cell 34, 466–482 (2018).
pubmed: 30174241
pmcid: 6152943
doi: 10.1016/j.ccell.2018.08.001
Reynolds, G. et al. Developmental cell programs are co-opted in inflammatory skin disease. Science 371, eaba6500 (2021).
pubmed: 33479125
pmcid: 7611557
doi: 10.1126/science.aba6500
Sharma, A. et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell 183, 377–394 (2020).
pubmed: 32976798
doi: 10.1016/j.cell.2020.08.040
Chen, Y. et al. Type-I collagen produced by distinct fibroblast lineages reveals specific function during embryogenesis and osteogenesis imperfecta. Nat. Commun. 12, 7199 (2021).
pubmed: 34893625
pmcid: 8664945
doi: 10.1038/s41467-021-27563-3
Ramadan, R. et al. The extracellular matrix controls stem cell specification and crypt morphology in the developing and adult mouse gut. Biology Open 11, bio059544 (2022).
Chen, Y. et al. Oncogenic collagen I homotrimers from cancer cells bind to α
pubmed: 35868307
pmcid: 9831277
doi: 10.1016/j.ccell.2022.06.011
Wei, S. C. et al. Matrix stiffness drives epithelial–mesenchymal transition and tumour metastasis through a TWIST1–G3BP2 mechanotransduction pathway. Nat. Cell Biol. 17, 678–688 (2015).
pubmed: 25893917
pmcid: 4452027
doi: 10.1038/ncb3157
Brügger, M. D., Valenta, T., Fazilaty, H., Hausmann, G. & Basler, K. Distinct populations of crypt-associated fibroblasts act as signaling hubs to control colon homeostasis. PLoS Biol. 18, e3001032 (2020).
pubmed: 33306673
pmcid: 7758045
doi: 10.1371/journal.pbio.3001032
Degirmenci, B., Valenta, T., Dimitrieva, S., Hausmann, G. & Basler, K. GLI1-expressing mesenchymal cells form the essential Wnt-secreting niche for colon stem cells. Nature 558, 449–453 (2018).
pubmed: 29875413
doi: 10.1038/s41586-018-0190-3
Kwon, O.-J., Zhang, L., Ittmann, M. M. & Xin, L. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc. Natl Acad. Sci. USA 111, E592–E600 (2014).
pubmed: 24367088
doi: 10.1073/pnas.1318157111
Qin, H. et al. SOX9 in prostate cancer is upregulated by cancer-associated fibroblasts to promote tumor progression through HGF/c-Met–FRA1 signaling. FEBS J. 288, 5406–5429 (2021).
pubmed: 33705609
doi: 10.1111/febs.15816
Lee, K.-W. et al. PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression. Nat. Commun. 13, 2793 (2022).
pubmed: 35589735
pmcid: 9120014
doi: 10.1038/s41467-022-30484-4
Arumi-Planas, M. et al. Microenvironmental Snail1-induced immunosuppression promotes melanoma growth. Oncogene 42, 2659–2672 (2023).
Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564–576 (2017).
pubmed: 28753430
pmcid: 5667678
doi: 10.1016/j.cell.2017.06.010
Giraddi, R. R. et al. Single-cell transcriptomes distinguish stem cell state changes and lineage specification programs in early mammary gland development. Cell Rep. 24, 1653–1666 (2018).
pubmed: 30089273
pmcid: 6301014
doi: 10.1016/j.celrep.2018.07.025
Pal, B. et al. Construction of developmental lineage relationships in the mouse mammary gland by single-cell RNA profiling. Nat. Commun. 8, 1627 (2017).
pubmed: 29158510
pmcid: 5696379
doi: 10.1038/s41467-017-01560-x
Liu, Y. & Guo, W. SOX factors as cell-state regulators in the mammary gland and breast cancer. Semin. Cell Dev. Biol. 114, 126–133 (2021).
pubmed: 33583737
pmcid: 8154634
doi: 10.1016/j.semcdb.2021.01.002
Wuidart, A. et al. Early lineage segregation of multipotent embryonic mammary gland progenitors. Nat. Cell Biol. 20, 666–676 (2018).
pubmed: 29784918
pmcid: 5985933
doi: 10.1038/s41556-018-0095-2
Chakrabarti, R. et al. ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat. Cell Biol. 16, 1004–1015 (2014).
pubmed: 25241036
pmcid: 4183725
doi: 10.1038/ncb3040
Bagati, A. et al. Integrin α
pubmed: 33385331
doi: 10.1016/j.ccell.2020.12.001
Roukens, M. G. et al. Regulation of a progenitor gene program by SOX4 is essential for mammary tumor proliferation. Oncogene 40, 6343–6353 (2021).
pubmed: 34584219
pmcid: 8585668
doi: 10.1038/s41388-021-02004-z
Tiwari, N. et al. Sox4 is a master regulator of epithelial–mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 23, 768–783 (2013).
pubmed: 23764001
doi: 10.1016/j.ccr.2013.04.020
Oliemuller, E. et al. SOX11 promotes invasive growth and ductal carcinoma in situ progression: SOX11 promotes invasion and DCIS progression. J. Pathol. 243, 193–207 (2017).
pubmed: 28707729
pmcid: 5637904
doi: 10.1002/path.4939
Zvelebil, M. et al. Embryonic mammary signature subsets are activated in Brca1
pubmed: 23506684
pmcid: 3672751
doi: 10.1186/bcr3403
Wen, W. et al. Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. Nat. Commun. 12, 5318 (2021).
pubmed: 34518541
pmcid: 8438084
doi: 10.1038/s41467-021-25670-9
Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D. & Carroll, J. S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 43, 27–33 (2011).
pubmed: 21151129
doi: 10.1038/ng.730
Fu, X. et al. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proc. Natl Acad. Sci. USA 116, 26823–26834 (2019).
pubmed: 31826955
pmcid: 6936436
doi: 10.1073/pnas.1911584116
Sherwood, R. I., Chen, T.-Y. A. & Melton, D. A. Transcriptional dynamics of endodermal organ formation. Dev. Dyn. 238, 29–42 (2009).
pubmed: 19097184
pmcid: 3756511
doi: 10.1002/dvdy.21810
Francis, R. et al. Gastrointestinal transcription factors drive lineage-specific developmental programs in organ specification and cancer. Sci. Adv. 5, eaax8898 (2019).
pubmed: 31844668
pmcid: 6905862
doi: 10.1126/sciadv.aax8898
Salari, K. et al. CDX2 is an amplified lineage-survival oncogene in colorectal cancer. Proc. Natl Acad. Sci. USA 109, E3196–E3205 (2012).
pubmed: 23112155
pmcid: 3503165
doi: 10.1073/pnas.1206004109
Gold, P. & Freedman, S. O. Specific carcinoembryonic antigens of the human digestive system. J. Exp. Med. 122, 467–481 (1965).
pubmed: 4953873
pmcid: 2138078
doi: 10.1084/jem.122.3.467
Banwo, O., Versey, J. & Hobbs, J. R. New oncofetal antigen for human pancreas. Lancet 303, 643–645 (1974).
doi: 10.1016/S0140-6736(74)93197-3
Pattabiraman, D. R. et al. Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability. Science 351, aad3680 (2016).
pubmed: 26941323
pmcid: 5131720
doi: 10.1126/science.aad3680
Cassier, P. A. et al. Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer. Nature 620, 409–416 (2023).
Lengrand, J. et al. Pharmacological targeting of netrin-1 inhibits EMT in cancer. Nature 620, 402–408 (2023).
Ishay-Ronen, D. et al. Gain fat—lose metastasis: converting invasive breast cancer cells into adipocytes inhibits cancer metastasis. Cancer Cell 35, 17–32 (2019).
pubmed: 30645973
doi: 10.1016/j.ccell.2018.12.002
Terry, S. et al. New insights into the role of EMT in tumor immune escape. Mol. Oncol. 11, 824–846 (2017).
pubmed: 28614624
pmcid: 5496499
doi: 10.1002/1878-0261.12093
Dongre, A. et al. Direct and indirect regulators of epithelial–mesenchymal transition-mediated immunosuppression in breast carcinomas. Cancer Discov. 11, 1286–1305 (2021).
pubmed: 33328216
doi: 10.1158/2159-8290.CD-20-0603
Hu, J. et al. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature 616, 806–813 (2023).
pubmed: 36991128
pmcid: 10569211
doi: 10.1038/s41586-023-05880-5
Storer, M. et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell 155, 1119–1130 (2013).
pubmed: 24238961
doi: 10.1016/j.cell.2013.10.041
Milanovic, M., Yu, Y. & Schmitt, C. A. The senescence–stemness alliance — a cancer-hijacked regeneration principle. Trends Cell Biol. 28, 1049–1061 (2018).
pubmed: 30253901
doi: 10.1016/j.tcb.2018.09.001
Hüser, L., Novak, D., Umansky, V., Altevogt, P. & Utikal, J. Targeting SOX2 in anticancer therapy. Expert Opin. Ther. Targets 22, 983–991 (2018).
Luo, Z. et al. Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis. Nature 612, 787–794 (2022).
Chen, Y. et al. Reversible reprogramming of cardiomyocytes to a fetal state drives heart regeneration in mice. Science 373, 1537–1540 (2021).
pubmed: 34554778
doi: 10.1126/science.abg5159
Chen, J., Ju, H. L., Yuan, X. Y., Wang, T. J. & Lai, B. Q. SOX4 is a potential prognostic factor in human cancers: a systematic review and meta-analysis. Clin. Transl. Oncol. 18, 65–72 (2016).
pubmed: 26250764
doi: 10.1007/s12094-015-1337-4
Pomerantz, M. M. et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat. Genet. 52, 790–799 (2020).
pubmed: 32690948
pmcid: 10007911
doi: 10.1038/s41588-020-0664-8
Ma, F. et al. SOX9 drives WNT pathway activation in prostate cancer. J. Clin. Invest. 126, 1745–1758 (2016).
pubmed: 27043282
pmcid: 4855922
doi: 10.1172/JCI78815
Mu, P. et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355, 84–88 (2017).
pubmed: 28059768
pmcid: 5247742
doi: 10.1126/science.aah4307
Rudin, C. M. et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44, 1111–1116 (2012).
pubmed: 22941189
pmcid: 3557461
doi: 10.1038/ng.2405
Tanaka, H. et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res. 67, 6007–6011 (2007).
pubmed: 17616654
doi: 10.1158/0008-5472.CAN-06-4774
Jing, X., Wang, T., Huang, S., Glorioso, J. C. & Albers, K. M. The transcription factor Sox11 promotes nerve regeneration through activation of the regeneration-associated gene Sprr1a. Exp. Neurol. 233, 221–232 (2012).
pubmed: 22024412
doi: 10.1016/j.expneurol.2011.10.005
Hamon, A., Roger, J. E., Yang, X.-J. & Perron, M. Müller glial cell-dependent regeneration of the neural retina: an overview across vertebrate model systems. Dev. Dyn. 245, 727–738 (2016).
pubmed: 26661417
pmcid: 4900950
doi: 10.1002/dvdy.24375
Decaesteker, B. et al. SOX11 regulates SWI/SNF complex components as member of the adrenergic neuroblastoma core regulatory circuitry. Nat. Commun. 14, 1267 (2023).
pubmed: 36882421
pmcid: 9992472
doi: 10.1038/s41467-023-36735-2
Angelozzi, M., da Silva, R. P., Gonzalez, M. V. & Lefebvre, V. Single-cell atlas of craniogenesis uncovers SOXC-dependent, highly proliferative, and myofibroblast-like osteodermal progenitors. Cell Rep. 40, 111045 (2022).
pubmed: 35830813
pmcid: 9595211
doi: 10.1016/j.celrep.2022.111045
Storz, P. Acinar cell plasticity and development of pancreatic ductal adenocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 14, 296–304 (2017).
pubmed: 28270694
pmcid: 6036907
doi: 10.1038/nrgastro.2017.12
Dassaye, R., Naidoo, S. & Cerf, M. E. Transcription factor regulation of pancreatic organogenesis, differentiation and maturation. Islets 8, 13–34 (2015).
pubmed: 26404721
pmcid: 4878272
doi: 10.1080/19382014.2015.1075687
Patel, S. A. et al. The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer. Nature 606, 999–1006 (2022).
pubmed: 35676472
pmcid: 9242860
doi: 10.1038/s41586-022-04809-8
Imgrund, M. et al. Re-expression of the developmental gene Pax-2 during experimental acute tubular necrosis in mice. Kidney Int. 56, 1423–1431 (1999).
pubmed: 10504494
doi: 10.1046/j.1523-1755.1999.00663.x
Kimura, S. Thyroid-specific transcription factors and their roles in thyroid cancer. J. Thyroid Res. 2011, e710213 (2011).
doi: 10.4061/2011/710213
Vu-Phan, D. et al. The thyroid cancer PAX8–PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype. Endocr. Relat. Cancer 20, 725–739 (2013).
pubmed: 24025583
doi: 10.1530/ERC-13-0058
Shakhova, O. et al. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat. Cell Biol. 14, 882–890 (2012).
pubmed: 22772081
doi: 10.1038/ncb2535
Garraway, L. A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117–122 (2005).
pubmed: 16001072
doi: 10.1038/nature03664
Miao, Q. et al. SOX11 and SOX4 drive the reactivation of an embryonic gene program during murine wound repair. Nat. Commun. 10, 4042 (2019).
pubmed: 31492871
pmcid: 6731344
doi: 10.1038/s41467-019-11880-9
Limaye, P. B. et al. Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development. Lab. Invest. 88, 865–872 (2008).
pubmed: 18574450
pmcid: 2631390
doi: 10.1038/labinvest.2008.56
Sun, R. et al. SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2. Cell Death Dis. 6, e1990 (2015).
Mills, J. C., Stanger, B. Z. & Sander, M. Nomenclature for cellular plasticity: are the terms as plastic as the cells themselves? EMBO J. 38, e103148 (2019).
pubmed: 31475380
pmcid: 6769377
doi: 10.15252/embj.2019103148